Figure 2

Mouse weight control during the injury acute phase of SCI after preventive (A) GSE and (B) CE treatment and biomarkers quantification of (C,D) hepatotoxicity and (E) nephrotoxicity in the serum of each experimental group at the end of the experimental period. The results are represented as the mean ± SEM. The treatment administration week (basal to 7 dpi) is highlighted with a thick black line (A,B). a–b: Groups not sharing a letter showed significant differences, p < 0.05. Experimental groups (A-B): Sham (n = 11), SCI + Saline (n = 18), SCI + GSE10 (n = 16), SCI + GSE15 (n = 14), SCI + GSE20 (n = 12), SCI + CE10 (n = 8), SCI + CE15 (n = 8). Experimental groups (C-E): Sham (ALT/GTP n = 6; AST/GOT n = 6; UREA n = 6), SCI + Saline (ALT/GTP n = 6; AST/GOT n = 6; UREA n = 6), SCI + GSE10 (ALT/GTP n = 6; AST/GOT n = 5; UREA n = 6), SCI + GSE15 (ALT/GTP n = 5; AST/GOT n = 6; UREA n = 7), SCI + GSE20 (ALT/GTP n = 5; AST/GOT n = 5; UREA n = 5), SCI + CE10 (ALT/GTP n = 5; AST/GOT n = 5; UREA n = 6), SCI + CE15 (ALT/GTP n = 6; AST/GOT n = 6; UREA n = 6).